Akorn, Inc. (AKRX): Price and Financial Metrics

Akorn, Inc. (AKRX): $0.09

0.09 (-51.01%)

POWR Rating

Component Grades








Add AKRX to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




in industry

AKRX Price/Volume Stats

Current price $0.09 52-week high $5.46
Prev. close $0.18 52-week low $0.09
Day low $0.09 Volume 36,138,500
Day high $0.20 Avg. volume 9,601,876
50-day MA $0.30 Dividend yield N/A
200-day MA $2.15 Market Cap 11.98M

AKRX Stock Price Chart Interactive Chart >

Akorn, Inc. (AKRX) Company Bio

Akorn Inc. manufactures, and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter consumer health products in the United States and internationally. It operates through two segments, Prescription Pharmaceuticals and Consumer Health. The company was founded in 1971 and is based in Lake Forest, Illinois.

AKRX Latest News Stream

Event/Time News Detail
Loading, please wait...

AKRX Latest Social Stream

Loading social stream, please wait...

View Full AKRX Social Stream

Latest AKRX News From Around the Web

Below are the latest news stories about Akorn Inc that investors may wish to consider to help them evaluate AKRX as an investment opportunity.

WeWork Board Factions Head for Clash Over New Directors

(Bloomberg) -- WeWork’s board is scheduled to vote on appointing two new directors on Friday, a critical step in a clash between shareholder SoftBank Group Corp. and a rival faction at the troubled co-working startup.A lawyer for WeWork told Delaware Chancery Court Judge Andre Bouchard in a letter that the company plans a May 29 meeting to fill two empty independent director seats. The nominees are Alex Dimitrief, General Electric Co.’s ex-top lawyer, and Frederick Arnold, the former chief financial officer for Convergex Group.SoftBank and the rival board faction are feuding over the Japanese conglomerate’s decision to scrap a $3 billion deal to buy stock from WeWork’s former Chief Executive Officer Adam Neumann and other shareholders. SoftBank agreed to the purchase last year as it bai...

Yahoo | May 28, 2020

Akorn, Inc. -- Moody's downgrades Akorn's PDR to D-PD following Chapter 11 filing

Moody's Investors Service ("Moody's") downgraded Akorn, Inc.'s ("Akorn") Probability of Default Rating to D-PD from Ca-PD. This follows Akorn's May 20, 2020 announcement that it filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code[1]. Moody's also affirmed Akorn's other existing ratings including the Caa3 Corporate Family Rating and Caa3 senior secured term loan rating.

Yahoo | May 26, 2020

Akorn Seeks Bankruptcy After Failed Takeover, FDA Warnings

(Bloomberg) -- Akorn Inc. sought bankruptcy protection from creditors after a series of deficiencies uncovered about its quality-control methods resulted in the collapse of rival Fresenius SA’s buyout of the generic drugmaker and subsequent warning letters from the U.S. Food and Drug Administration.The Lake Forest, Illinois-based company listed as much as $10 billion of debt and $10 billion of assets in its Chapter 11 petition, filed on Wednesday in the Delaware bankruptcy court.In December of 2018, Fresenius SE backed out of its $4.3 billion offer for the company after it discovered issues with Akorn’s pharmaceutical production, quality control and drug testing. A Delaware judge later blessed that decision and is still considering whether Akorn owes Fresenius more than $70 million in d...

Yahoo | May 22, 2020

Drugmaker Akorn files for bankruptcy protection after failed sale

Generic drugmaker Akorn Inc filed for bankruptcy protection late Wednesday, citing the overhang of litigation stemming from German healthcare company Fresenius SE's decision two years ago to terminate an over $4 billion acquisition of the company.

Reuters | May 21, 2020

The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Th...

Benzinga | May 21, 2020

Read More 'AKRX' Stories Here

AKRX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year -98.06%
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 -55.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!